Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer.

Wang F, Reid S, Zheng W, Pal T, Meszoely I, Mayer IA, Bailey CE, Park BH, Shu XO.

Clin Cancer Res. 2019 Nov 20. doi: 10.1158/1078-0432.CCR-19-2424. [Epub ahead of print]

PMID:
31748278
2.

Overall Mortality After Diagnosis of Breast Cancer in Men vs Women.

Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, Zheng W, Bailey CE, Shu XO.

JAMA Oncol. 2019 Sep 19. doi: 10.1001/jamaoncol.2019.2803. [Epub ahead of print]

PMID:
31536134
3.

Correction: Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.

Cancer Res. 2019 Feb 15;79(4):876. doi: 10.1158/0008-5472.CAN-18-4088. No abstract available.

PMID:
30770371
4.

Molecular determinants of post-mastectomy breast cancer recurrence.

Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F.

NPJ Breast Cancer. 2018 Oct 12;4:34. doi: 10.1038/s41523-018-0089-z. eCollection 2018.

5.

Toward quantitative quasistatic elastography with a gravity-induced deformation source for image-guided breast surgery.

Griesenauer RH, Weis JA, Arlinghaus LR, Meszoely IM, Miga MI.

J Med Imaging (Bellingham). 2018 Jan;5(1):015003. doi: 10.1117/1.JMI.5.1.015003. Epub 2018 Feb 8.

6.

A system for automatic monitoring of surgical instruments and dynamic, non-rigid surface deformations in breast cancer surgery.

Richey WL, Luo M, Goodale SE, Clements LW, Meszoely IM, Miga MI.

Proc SPIE Int Soc Opt Eng. 2018 Feb;10576. pii: 105761H. doi: 10.1117/12.2295221. Epub 2018 Mar 13.

7.

Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment.

Thomas G, Nguyen TQ, Pence IJ, Caldwell B, O'Connor ME, Giltnane J, Sanders ME, Grau A, Meszoely I, Hooks M, Kelley MC, Mahadevan-Jansen A.

Sci Rep. 2017 Oct 19;7(1):13548. doi: 10.1038/s41598-017-13237-y.

8.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance.

Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, Mayer IA, Abramson V, Gόmez H, Rizzo M, Toy W, Chandarlapaty S, Mayer EL, Christiansen J, Murphy D, Fitzgerald K, Wang K, Ross JS, Miller VA, Stephens PJ, Yelensky R, Garraway L, Shyr Y, Meszoely I, Balko JM, Arteaga CL.

Sci Transl Med. 2017 Aug 9;9(402). pii: eaai7993. doi: 10.1126/scitranslmed.aai7993. Erratum in: Sci Transl Med. 2019 Feb 13;11(479):.

9.

Breast tissue stiffness estimation for surgical guidance using gravity-induced excitation.

Griesenauer RH, Weis JA, Arlinghaus LR, Meszoely IM, Miga MI.

Phys Med Biol. 2017 Jun 21;62(12):4756-4776. doi: 10.1088/1361-6560/aa700a. Epub 2017 May 18.

10.

Bilateral Changes in Deep Tissue Environment After Manual Lymphatic Drainage in Patients with Breast Cancer Treatment-Related Lymphedema.

Donahue PM, Crescenzi R, Scott AO, Braxton V, Desai A, Smith SA, Jordi J, Meszoely IM, Grau AM, Kauffmann RM, Sweeting RS, Spotanski K, Ridner SH, Donahue MJ.

Lymphat Res Biol. 2017 Mar;15(1):45-56. doi: 10.1089/lrb.2016.0020.

11.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

12.

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.

King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA.

J Clin Oncol. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21.

13.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
14.

Realization of a biomechanical model-assisted image guidance system for breast cancer surgery using supine MRI.

Conley RH, Meszoely IM, Weis JA, Pheiffer TS, Arlinghaus LR, Yankeelov TE, Miga MI.

Int J Comput Assist Radiol Surg. 2015 Dec;10(12):1985-96. doi: 10.1007/s11548-015-1235-9. Epub 2015 Jun 20.

15.

Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.

Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F, Sanders M, Dugger TC, Allen EV, Arteaga CL.

Cancer Res. 2015 Jan 15;75(2):405-14. doi: 10.1158/0008-5472.CAN-14-2475. Epub 2014 Dec 5. Erratum in: Cancer Res. 2019 Feb 15;79(4):876.

16.

LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.

Schwarz LJ, Fox EM, Balko JM, Garrett JT, Kuba MG, Estrada MV, González-Angulo AM, Mills GB, Red-Brewer M, Mayer IA, Abramson V, Rizzo M, Kelley MC, Meszoely IM, Arteaga CL.

J Clin Invest. 2014 Dec;124(12):5490-502. doi: 10.1172/JCI72573. Epub 2014 Nov 17.

17.

Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.

Li X, Abramson RG, Arlinghaus LR, Kang H, Chakravarthy AB, Abramson VG, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Yankeelov TE.

Invest Radiol. 2015 Apr;50(4):195-204. doi: 10.1097/RLI.0000000000000100.

18.

Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.

McGuire KP, Hwang ES, Cantor A, Golshan M, Meric-Bernstam F, Horton JK, Nanda R, Amos KD, Forero A, Hudis CA, Meszoely I, De Los Santos JF.

Ann Surg Oncol. 2015 Jan;22(1):75-81. doi: 10.1245/s10434-014-3948-3. Epub 2014 Jul 25.

19.

DCE-MRI analysis methods for predicting the response of breast cancer to neoadjuvant chemotherapy: pilot study findings.

Li X, Arlinghaus LR, Ayers GD, Chakravarthy AB, Abramson RG, Abramson VG, Atuegwu N, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Grau AM, Sanders M, Bhave SR, Yankeelov TE.

Magn Reson Med. 2014 Apr;71(4):1592-602. doi: 10.1002/mrm.24782. Epub 2013 May 9.

20.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

21.

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.

Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL.

Mol Cancer Ther. 2012 Oct;11(10):2301-5. doi: 10.1158/1535-7163.MCT-12-0511. Epub 2012 Aug 9.

22.

Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL.

Nat Med. 2012 Jul;18(7):1052-9. doi: 10.1038/nm.2795.

23.

Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer.

Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, Mayer IA, Kelley MC, Meszoely IM, Means-Powell J, Abramson VG, Grau AM, Gore JC, Yankeelov TE.

Magn Reson Med. 2012 Jul;68(1):261-71. doi: 10.1002/mrm.23205. Epub 2011 Nov 29.

24.

A novel AIF tracking method and comparison of DCE-MRI parameters using individual and population-based AIFs in human breast cancer.

Li X, Welch EB, Arlinghaus LR, Chakravarthy AB, Xu L, Farley J, Loveless ME, Mayer IA, Kelley MC, Meszoely IM, Means-Powell JA, Abramson VG, Grau AM, Gore JC, Yankeelov TE.

Phys Med Biol. 2011 Sep 7;56(17):5753-69. doi: 10.1088/0031-9155/56/17/018. Epub 2011 Aug 12.

25.

Motion correction in diffusion-weighted MRI of the breast at 3T.

Arlinghaus LR, Welch EB, Chakravarthy AB, Xu L, Farley JS, Abramson VG, Grau AM, Kelley MC, Mayer IA, Means-Powell JA, Meszoely IM, Gore JC, Yankeelov TE.

J Magn Reson Imaging. 2011 May;33(5):1063-70. doi: 10.1002/jmri.22562.

26.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
27.

Validation of an algorithm for the nonrigid registration of longitudinal breast MR images using realistic phantoms.

Li X, Dawant BM, Welch EB, Chakravarthy AB, Xu L, Mayer I, Kelley M, Meszoely I, Means-Powell J, Gore JC, Yankeelov TE.

Med Phys. 2010 Jun;37(6):2541-52.

28.

Autofluorescence and diffuse reflectance spectroscopy and spectral imaging for breast surgical margin analysis.

Keller MD, Majumder SK, Kelley MC, Meszoely IM, Boulos FI, Olivares GM, Mahadevan-Jansen A.

Lasers Surg Med. 2010 Jan;42(1):15-23. doi: 10.1002/lsm.20865.

PMID:
20077490
29.

Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.

Bauer JA, Chakravarthy AB, Rosenbluth JM, Mi D, Seeley EH, De Matos Granja-Ingram N, Olivares MG, Kelley MC, Mayer IA, Meszoely IM, Means-Powell JA, Johnson KN, Tsai CJ, Ayers GD, Sanders ME, Schneider RJ, Formenti SC, Caprioli RM, Pietenpol JA.

Clin Cancer Res. 2010 Jan 15;16(2):681-90. doi: 10.1158/1078-0432.CCR-09-1091. Epub 2010 Jan 12.

30.

A nonrigid registration algorithm for longitudinal breast MR images and the analysis of breast tumor response.

Li X, Dawant BM, Welch EB, Chakravarthy AB, Freehardt D, Mayer I, Kelley M, Meszoely I, Gore JC, Yankeelov TE.

Magn Reson Imaging. 2009 Nov;27(9):1258-70. doi: 10.1016/j.mri.2009.05.007. Epub 2009 Jun 13.

31.

Evaluation of biological agents targeted at early-stage disease.

Guix M, Mayer IA, Meszoely IM, Arteaga CL.

Breast Cancer Res. 2008;10 Suppl 4:S25. doi: 10.1186/bcr2185. Epub 2008 Dec 18. No abstract available.

32.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

PMID:
18180460
33.

Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results.

Yankeelov TE, Lepage M, Chakravarthy A, Broome EE, Niermann KJ, Kelley MC, Meszoely I, Mayer IA, Herman CR, McManus K, Price RR, Gore JC.

Magn Reson Imaging. 2007 Jan;25(1):1-13. Epub 2006 Nov 21.

34.

Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates.

Means AL, Meszoely IM, Suzuki K, Miyamoto Y, Rustgi AK, Coffey RJ Jr, Wright CV, Stoffers DA, Leach SD.

Development. 2005 Aug;132(16):3767-76. Epub 2005 Jul 14.

35.

Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003.

Meszoely IM, Wang H, Hoffman JP.

Surg Oncol Clin N Am. 2004 Oct;13(4):685-96, x. Review.

PMID:
15350942
36.

Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.

Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.

Ann Surg Oncol. 2004 Jul;11(7):644-9. Epub 2004 Jun 14.

PMID:
15197014
37.

Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas.

Meszoely IM, Lee JS, Watson JC, Meyers M, Wang H, Hoffman JP.

Am Surg. 2004 Mar;70(3):208-13; discussion 213-4.

PMID:
15055843
38.

Is reporting of recurrence data important in pancreatic cancer?

Meyers MO, Meszoely IM, Hoffman JP, Watson JC, Ross E, Eisenberg BL.

Ann Surg Oncol. 2004 Mar;11(3):304-9.

PMID:
14993026
39.

Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis.

Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, Leach SD.

Cancer Cell. 2003 Jun;3(6):565-76.

40.

Developmental aspects of early pancreatic cancer.

Meszoely IM, Means AL, Scoggins CR, Leach SD.

Cancer J. 2001 Jul-Aug;7(4):242-50. Review.

PMID:
11561600
41.

p53-dependent acinar cell apoptosis triggers epithelial proliferation in duct-ligated murine pancreas.

Scoggins CR, Meszoely IM, Wada M, Means AL, Yang L, Leach SD.

Am J Physiol Gastrointest Liver Physiol. 2000 Oct;279(4):G827-36.

43.

Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha.

Song SY, Gannon M, Washington MK, Scoggins CR, Meszoely IM, Goldenring JR, Marino CR, Sandgren EP, Coffey RJ Jr, Wright CV, Leach SD.

Gastroenterology. 1999 Dec;117(6):1416-26.

PMID:
10579983
44.

Nonoperative management of primary colorectal cancer in patients with stage IV disease.

Scoggins CR, Meszoely IM, Blanke CD, Beauchamp RD, Leach SD.

Ann Surg Oncol. 1999 Oct-Nov;6(7):651-7.

PMID:
10560850
45.

New trends in gastrointestinal surgical oncology.

Meszoely IM, Chapman WC, Holzman MD, Leach SD.

Cancer Treat Res. 1998;98:239-91. Review. No abstract available.

PMID:
10326672
46.

Aortoiliac occlusive disease and gastrointestinal malignancy: changing therapeutic options.

Neuzil DF, Meszoely I, Tarpley JL, Naslund TC.

Am Surg. 1998 Apr;64(4):293-7.

PMID:
9544135
47.

Hypothalamic Na(+)-K(+)-ATPase inhibitor characterized in two-sided liposomes containing pure renal Na(+)-K(+)-ATPase.

Anner BM, Rey HG, Moosmayer M, Meszoely I, Haupert GT Jr.

Am J Physiol. 1990 Jan;258(1 Pt 2):F144-53.

PMID:
2154124

Supplemental Content

Loading ...
Support Center